Yanjun Xu

12PUBLICATIONS
17CO-AUTHORS
Predictive and prognostic markersCancer geneticsMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Allergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 22, 2026
Lorlatinib-specific outcomes by timing of lorlatinib initiation in advanced ALK-positive non-small cell lung cancer: A retrospective cohort study.

|Apr 28, 2026
A real-world study on the comparative effectiveness of first-line treatment regimens in advanced NSCLC patients with PACC mutations.

|Dec 22, 2025
Clinicopathologic features and therapeutic outcomes in EGFR/ALK-aberrations NSCLC with histologic transformation.

Kaibo Ding, Xinyue Li, Hui Li

|Nov 17, 2025
Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy.

Dujiang Liu, Kaibo Ding, Linjing Zhou

|Nov 06, 2025
Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies.

Sizhe Yu, Hui Li, Hongyang Lu

|Sep 04, 2025
Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: mechanisms and therapeutic challenges.

Xinyue Li, Kaibo Ding, Dujiang Liu

Pageof 2

Frequent Collaborators

3 joint publications

Hui Li

3 joint publications

Yun Fan

2 joint publications

Zhongsheng Peng

2 joint publications

Ling Ding